JAMA Dermatology

<jats:sec id="ab-doi230038-4"><jats:title>Importance</jats:title><jats:p>The gut microbiome modulates the immune system and responses to immunotherapy in patients with late-stage melanoma. It is unknown whether fecal microbiota profiles differ between healthy individuals and patients with melanoma or if microbiota profiles differ among patients with different stages of melanoma. Defining gut microbiota profiles in individuals without melanoma and those with early-stage and late-stage melanoma may reveal features associated with disease progression.</jats:p></jats:sec><jats:sec id="ab-doi230038-5"><jats:title>Objective</jats:title><jats:p>To characterize and compare gut microbiota profiles between healthy volunteers and patients with melanoma and between patients with early-stage and late-stage melanoma.</jats:p></jats:sec><jats:sec id="ab-doi230038-6"><jats:title>Design, Setting, and Participants</jats:title><jats:p>This single-site case-control study took place at an academic comprehensive cancer center. Fecal samples were collected from systemic treatment−naive patients with stage I to IV melanoma from June 1, 2015, to January 31, 2019, and from healthy volunteers from June 1, 2021, to January 31, 2022. Patients were followed up for disease recurrence until November 30, 2021.</jats:p></jats:sec><jats:sec id="ab-doi230038-7"><jats:title>Main Outcomes and Measures</jats:title><jats:p>Fecal microbiota was profiled by 16S ribosomal RNA sequencing. Clinical and pathologic characteristics, treatment, and disease recurrence were extracted from electronic medical records. Fecal microbiome diversity, taxonomic profiles and inferred functional profiles were compared between groups.</jats:p></jats:sec><jats:sec id="ab-doi230038-8"><jats:title>Results</jats:title><jats:p>A total of 228 participants were enrolled (126 men [55.3%]; median age, 59 [range, 21-90] years), including 49 volunteers without melanoma, 38 patients with early-stage melanoma (29 with stage I or melanoma in situ and 9 with stage II), and 141 with late-stage melanoma (66 with stage III and 75 with stage IV). Community differences were observed between patients with melanoma and volunteers. Patients with melanoma had a higher relative abundance of <jats:italic>Fusobacterium</jats:italic> compared with controls on univariate analysis (0.19% vs 0.003%; <jats:italic>P</jats:italic> &amp;amp;lt; .001), but this association was attenuated when adjusted for covariates (log2 fold change of 5.18 vs controls; <jats:italic>P</jats:italic> = .09). Microbiomes were distinct between patients with early-stage and late-stage melanoma. Early-stage melanoma had a higher alpha diversity (Inverse Simpson Index 14.6 [IQR, 9.8-23.0] vs 10.8 [IQR, 7.2-16.8]; <jats:italic>P</jats:italic> = .003), and a higher abundance of the genus <jats:italic>Roseburia</jats:italic> on univariate analysis (2.4% vs 1.2%; <jats:italic>P</jats:italic> &amp;amp;lt; .001) though statistical significance was lost with covariate adjustment (log2 fold change of 0.86 vs controls; <jats:italic>P</jats:italic> = .13). Multiple functional pathways were differentially enriched between groups. No associations were observed between the microbial taxa and disease recurrence in patients with stage III melanoma treated with adjuvant immunotherapy.</jats:p></jats:sec><jats:sec id="ab-doi230038-9"><jats:title>Conclusions and Relevance</jats:title><jats:p>The findings of this case-control study suggest that fecal microbiota profiles were significantly different among patients with melanoma and controls and between patients with early-stage and late-stage melanoma. Prospective investigations of the gut microbiome and changes that occur with disease progression may identify future microbial targets for intervention.</jats:p></jats:sec>

Modulating the microbiome to improve therapeutic response in cancer.

Lancet Oncol

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.

Science

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients.

Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients.

Neoplasia

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients.

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.

Ann Oncol

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients.

Genome Med

Tumor microbiome diversity and composition influence pancreatic cancer outcomes.

Cell

The gut microbiota influences anticancer immunosurveillance and general health.

Nat Rev Clin Oncol

The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy.

Cancer Cell

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.

Nat Med

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.

Cancer immunotherapy using checkpoint blockade.

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients.

Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors.

JAMA Netw Open

Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer.

Nat Commun

Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5-/- mice.

Dysbiosis of skin microbiome and gut microbiome in melanoma progression.

BMC Microbiol

The human skin microbiome.

Nat Rev Microbiol

Do the gut and skin microbiomes share thoughts on melanoma development?

Br J Dermatol

Early melanoma invasivity correlates with gut fungal and bacterial profiles.

Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

CA Cancer J Clin

Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms.

ISME J

KatharoSeq enables high-throughput microbiome analysis from low-biomass samples.

mSystems

Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities.

Appl Environ Microbiol

An ordination of the upland forest communities of southern Wisconsin.

Ecol Monogr

Analysis of compositions of microbiomes with bias correction.

Multivariable association discovery in population-scale meta-omics studies.

PLoS Comput Biol

Measurement of diversity.

Nature

Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.

Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy.

Fusobacterium nucleatum and T cells in colorectal carcinoma.

JAMA Oncol

Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut.

Tumour Biol

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti–PD-1.

Cancer induces a stress ileopathy depending on ß-adrenergic receptors and promoting dysbiosis that contributes to carcinogenesis.

Cancer Discov

Structure, function and diversity of the healthy human microbiome.

A human gut microbial gene catalogue established by metagenomic sequencing.

Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients.

Sci Rep

Oral microbiota community dynamics associated with oral squamous cell carcinoma staging.

Front Microbiol

Involvement of Fusobacterium species in oral cancer progression: a literature review including other types of cancer.

Int J Mol Sci

Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression.

Genomic analysis identifies association of Fusobacterium with colorectal carcinoma.

Genome Res

Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma.

Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients.

World J Gastroenterol

Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/ß-catenin signaling via its FadA adhesin.

Cell Host Microbe

Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc.

Fusobacterium nucleatum:  symbiont, opportunist and oncobacterium.

Assessing gut microbiota perturbations during the early phase of infectious diarrhea in Vietnamese children.

Gut Microbes

Diarrhea in young children from low-income countries leads to large-scale alterations in intestinal microbiota composition.

Genome Biol

Microbial translocation in chronic liver diseases.

Int J Microbiol

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.

Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration.

Contribution of acetate to butyrate formation by human faecal bacteria.

Br J Nutr

Oligonucleotide probes that detect quantitatively significant groups of butyrate-producing bacteria in human feces.

Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity.

Cell Metab

Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors.

The gut microbiome modulates the immune system and responses to immunotherapy in patients with late-stage melanoma. It is unknown whether fecal microbiota profiles differ between healthy individuals and patients with melanoma or if microbiota profiles differ among patients with different stages of melanoma. Defining gut microbiota profiles in individuals without melanoma and those with early-stage and late-stage melanoma may reveal features associated with disease progression.
To characterize and compare gut microbiota profiles between healthy volunteers and patients with melanoma and between patients with early-stage and late-stage melanoma.
This single-site case-control study took place at an academic comprehensive cancer center. Fecal samples were collected from systemic treatment-naive patients with stage I to IV melanoma from June 1, 2015, to January 31, 2019, and from healthy volunteers from June 1, 2021, to January 31, 2022. Patients were followed up for disease recurrence until November 30, 2021.
Fecal microbiota was profiled by 16S ribosomal RNA sequencing. Clinical and pathologic characteristics, treatment, and disease recurrence were extracted from electronic medical records. Fecal microbiome diversity, taxonomic profiles and inferred functional profiles were compared between groups.
A total of 228 participants were enrolled (126 men [55.3%]; median age, 59 [range, 21-90] years), including 49 volunteers without melanoma, 38 patients with early-stage melanoma (29 with stage I or melanoma in situ and 9 with stage II), and 141 with late-stage melanoma (66 with stage III and 75 with stage IV). Community differences were observed between patients with melanoma and volunteers. Patients with melanoma had a higher relative abundance of Fusobacterium compared with controls on univariate analysis (0.19% vs 0.003%; P < .001), but this association was attenuated when adjusted for covariates (log2 fold change of 5.18 vs controls; P = .09). Microbiomes were distinct between patients with early-stage and late-stage melanoma. Early-stage melanoma had a higher alpha diversity (Inverse Simpson Index 14.6 [IQR, 9.8-23.0] vs 10.8 [IQR, 7.2-16.8]; P = .003), and a higher abundance of the genus Roseburia on univariate analysis (2.4% vs 1.2%; P < .001) though statistical significance was lost with covariate adjustment (log2 fold change of 0.86 vs controls; P = .13). Multiple functional pathways were differentially enriched between groups. No associations were observed between the microbial taxa and disease recurrence in patients with stage III melanoma treated with adjuvant immunotherapy.
The findings of this case-control study suggest that fecal microbiota profiles were significantly different among patients with melanoma and controls and between patients with early-stage and late-stage melanoma. Prospective investigations of the gut microbiome and changes that occur with disease progression may identify future microbial targets for intervention.

Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma.

Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma

Papers